.jpg)
Over the past 6 months, Persist AI has developed cutting- edge robotics that enables automated development of long-acting injectable formulations
Persist AI, the AI-driven pioneer in drug formulation, announced today the close of an oversubscribed $4M financing round following their completion of YCombinator, the prestigious San Francisco based startup accelerator. The funding round was led by 2048 Ventures with the participation of Innospark Ventures, Fellows Fund, YCombinator, Pioneer Fund, and others.
Pharmaceutical companies typically take up to five years to develop long-lasting drug injections to treat chronic conditions such as cancer and diabetes. Enter Persist, leveraging AI-driven automation to slash formulation development time by a staggering 50% - to just two years. "We complete microsphere pre-formulation for clients in weeks, not years," stated CEO Karthik Raman."
Over the past 6 months, Persist AI has developed cutting- edge robotics that enables automated development of long-acting injectable formulations. Coupled with AI models, they are able to rapidly predict which formulations will release drugs in the body for a long time and reduce the number of injections that patients need.
"Drug formulation has long been overlooked despite being a crucial part of drug development. Persist's technology allows them to rapidly screen formulations, develop AI models that optimize the formulations, and then scale up formulations for human clinical use. We're excited to invest in this groundbreaking technology," said Alex Iskold, Managing partner of 2048 Ventures.
"Persist AI's disruptive approach to drug formulation holds immense promise for the future of drug development." Their AI-driven technology is set to revolutionize how we develop and optimize formulations for therapeutics of all kinds. We are proud to support their vision and contribute to their success," said Matt Fates, Partner, Innospark Ventures.
About Persist AI
Persist AI specializes in building and optimizing long-acting injectable formulations, offering high-throughput formulation screening, automated drug release testing, method transfer and manufacturing scale-up. This helps drug manufacturers solve problems with drug clearance in the body, formulation instability, acute toxicity, shelf life and many other drug formulation related problems.
SOURCE Persist AI Formulations
_______________________________________________________
FC Global Strategies enables medical, pharma, healthcare, medical device and healthcare IT companies to achieve their business and financial goals
Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives.
If your company has business or financial objectives check out:
Strategic advisory services provided by FC Global Strategies
Medical and Pharma Insider’s AI Connect Marketing Program
Medical and Pharma Insider is a program of FC Global Strategies.
Click here to schedule a call to discuss your company's business and financial goals.
FC Global Strategies' Contacts:
North America and Latin America
Jeffrey Friedland (Based in the US)
+1 646 450 8909
jeffrey@fcglobalstrategies.com
The Middle East, North Africa and Eastern Europe
David Krutonog (Based in Israel)
+972 50 974 3429
david@fcglobalstrategies.com
Southeast Asia, Asia-Pacific, Australia, and New Zealand
Ross Swan (Based in Singapore)
+65 9181 9472
ross@fcglobalstrategies.com
Latin America
Claudio Hebling (Based in Brazil)
+55 19 99377 7482
claudio@fcglobalstrategies.com
